valproic acid-expanded umbilical cord blood-derived CD34-positive cells
Term · Oncology and biomedicine · MLC-T-ONC-017451
A preparation of umbilical cord blood (UCB)-derived CD34-positive cells treated with valproic acid (VPA) with potential use in hematopoietic stem cell transplant (HSCT). Upon positive immunomagnetic selection of CD34-positive cells from UCB units, CD34-positive cells are expanded in culture with stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO), and interleukin-3 (IL-3), treated with VPA, and infused into the patient. VPA, a histone deacetylase inhibitor (HDACi), may induce epigenetic changes in UCB hematopoietic stem cells (HSCs), resulting in expansion of CD34-positive cells enriched in short term (ST), intermediate term (IT), and long term (LT) marrow repopulating cells (RCs), which are capable of sustained hematopoietic engraftment following transplantation. Further, VPA-expanded UCB stem cells may shorten the time to neutrophil and platelet recovery and maintain long-term hematopoietic and immune reconstitution compared to untreated UCB grafts.
| Identifier | MLC-T-ONC-017451 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | VPA-expanded cord blood stem cells; VPA-expanded UCB stem cells; VPA-expanded UCB-derived CD34-positive cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017451",
"term": "valproic acid-expanded umbilical cord blood-derived CD34-positive cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of umbilical cord blood (UCB)-derived CD34-positive cells treated with valproic acid (VPA) with potential use in hematopoietic stem cell transplant (HSCT). Upon positive immunomagnetic selection of CD34-positive cells from UCB units, CD34-positive cells are expanded in culture with stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO), and interleukin-3 (IL-3), treated with VPA, and infused into the patient. VPA, a histone deacetylase inhibitor (HDACi), may induce epigenetic changes in UCB hematopoietic stem cells (HSCs), resulting in expansion of CD34-positive cells enriched in short term (ST), intermediate term (IT), and long term (LT) marrow repopulating cells (RCs), which are capable of sustained hematopoietic engraftment following transplantation. Further, VPA-expanded UCB stem cells may shorten the time to neutrophil and platelet recovery and maintain long-term hematopoietic and immune reconstitution compared to untreated UCB grafts.",
"synonyms": [
"VPA-expanded cord blood stem cells",
"VPA-expanded UCB stem cells",
"VPA-expanded UCB-derived CD34-positive cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/valproic-acid-expanded-umbilical-cord-blood-derived-cd34-positive-cells/"
}
Record 17,097 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.